Comparison of Isolation Platforms for Detection of Circulating Renal Cell Carcinoma Cells

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Nov 21

PMID 29152114

Citations 29

Authors

Yvonne Maertens

Verena Humberg

Franziska Erlmeier

Sandra Steffens

Julie Steinestel

Martin Bogemann

Andres Jan Schrader

Christof Bernemann

Affiliations

Soon will be listed here.

Abstract

Background: Analysis of circulating tumor cells (CTCs) has progressed in several tumor entities. However, little is known about CTCs in clear cell renal cell carcinoma (ccRCC) patients. Aim of our studies was to build a stable fundament for isolation of CTCs in ccRCC.

Methods: We compared the analytical performance of different CTC isolation methods with regard to yield and purity: EpCAM based enrichment, leukocyte depletion and size based enrichment. EpCAM and cytokeratin 8 (KRT8) as biomarker for CTCs expression were evaluated in ccRCC cell lines as well as clinical samples.

Results: While the EpCAM based approach failed to successfully isolate tumor cells, CD45 based approaches showed intermediate recovery rates. The cell-size based Parsortix system showed highest recovery rates. EpCAM expression was low or absent in most cell lines as well as in clinical samples, whereas KRT8 was detected as a potential biomarker in ccRCC.

Conclusion: EpCAM based approaches might miss a high number of CTCs due to low or absent expression of EpCAM in ccRCC, as shown in cell lines as well as in patient samples. We identified the cell-sized based, label independent Parsortix system to be the most effective recovery system for ccRCC CTCs.

Citing Articles

Establishing cM0 (i+) stage criteria in localized renal cell carcinoma based on postoperative circulating tumor cells monitoring.

Chong Y, Zhou H, Zhang P, Xue L, Du Q, Chong T BMC Cancer. 2025; 25(1):436.

PMID: 40069681 PMC: 11895218. DOI: 10.1186/s12885-025-13815-8.

A Randomized Controlled Trial Assessing the Release of Circulating Tumor and Mesenchymal Cells in No-Touch Radical Nephrectomy.

Leitao T, Corredeira P, Rodrigues C, Piairo P, Miranda M, Cavaco A Cancers (Basel). 2024; 16(21).

PMID: 39518041 PMC: 11545310. DOI: 10.3390/cancers16213601.

The integrated on-chip isolation and detection of circulating tumour cells.

Abusamra S, Barber R, Sharafeldin M, Edwards C, Davis J Sens Diagn. 2024; 3(4):562-584.

PMID: 38646187 PMC: 11025039. DOI: 10.1039/d3sd00302g.

Clinical applications of circulating tumor cells in patients with solid tumors.

Smit D, Schneegans S, Pantel K Clin Exp Metastasis. 2024; 41(4):403-411.

PMID: 38281256 PMC: 11374849. DOI: 10.1007/s10585-024-10267-5.

Analytical performance of the FDA-cleared Parsortix PC1 system.

Templeman A, Miller M, Cooke M, OShannessy D, Gurung Y, Pereira T J Circ Biomark. 2023; 12:26-33.

PMID: 37601320 PMC: 10434983. DOI: 10.33393/jcb.2023.2629.

References

Chudziak J, Burt D, Mohan S, Rothwell D, Mesquita B, Antonello J . Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. Analyst. 2015; 141(2):669-78. DOI: 10.1039/c5an02156a. View

Bilkenroth U, Taubert H, Riemann D, Rebmann U, Heynemann H, Meye A . Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation. Int J Cancer. 2001; 92(4):577-82. DOI: 10.1002/ijc.1217. View

Nel I, Gauler T, Bublitz K, Lazaridis L, Goergens A, Giebel B . Circulating Tumor Cell Composition in Renal Cell Carcinoma. PLoS One. 2016; 11(4):e0153018. PMC: 4839694. DOI: 10.1371/journal.pone.0153018. View

Xu L, Mao X, Imrali A, Syed F, Mutsvangwa K, Berney D . Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System. PLoS One. 2015; 10(9):e0138032. PMC: 4580600. DOI: 10.1371/journal.pone.0138032. View

Kelloff G, Sigman C, Scher H . Biomarker development in the context of urologic cancers. Urol Oncol. 2015; 33(6):295-301. PMC: 4521394. DOI: 10.1016/j.urolonc.2015.01.007. View

Joosse S, Gorges T, Pantel K . Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2014; 7(1):1-11. PMC: 4309663. DOI: 10.15252/emmm.201303698. View

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Alix-Panabieres C, Pantel K . Challenges in circulating tumour cell research. Nat Rev Cancer. 2014; 14(9):623-31. DOI: 10.1038/nrc3820. View

McKiernan J, Buttyan R, Bander N, de la Taille A, Stifelman M, Emanuel E . The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer. 1999; 86(3):492-7. DOI: 10.1002/(sici)1097-0142(19990801)86:3<492::aid-cncr18>3.0.co;2-r. View

10.

Ashida S, Okuda H, Chikazawa M, Tanimura M, Sugita O, Yamamoto Y . Detection of circulating cancer cells with von hippel-lindau gene mutation in peripheral blood of patients with renal cell carcinoma. Clin Cancer Res. 2000; 6(10):3817-22. View

11.

Gradilone A, Iacovelli R, Cortesi E, Raimondi C, Gianni W, Nicolazzo C . Circulating tumor cells and "suspicious objects" evaluated through CellSearch® in metastatic renal cell carcinoma. Anticancer Res. 2011; 31(12):4219-21. View

12.

Allard W, Matera J, Miller M, Repollet M, Connelly M, Rao C . Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897-904. DOI: 10.1158/1078-0432.CCR-04-0378. View

13.

Liu S, Tian Z, Zhang L, Hou S, Hu S, Wu J . Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulating tumor cells in clear cell renal cell carcinoma patients. Oncotarget. 2016; 7(37):59877-59891. PMC: 5312355. DOI: 10.18632/oncotarget.10979. View

14.

Gorges T, Kuske A, Rock K, Mauermann O, Muller V, Peine S . Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells. Clin Chem. 2016; 62(11):1504-1515. DOI: 10.1373/clinchem.2016.260299. View

15.

Toss A, Mu Z, Fernandez S, Cristofanilli M . CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med. 2014; 2(11):108. PMC: 4245508. DOI: 10.3978/j.issn.2305-5839.2014.09.06. View

16.

Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B . Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3):920-8. DOI: 10.1158/1078-0432.CCR-06-1695. View

17.

Eichelberg C, Chun F, Bedke J, Heuer R, Adam M, Moch H . Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. Int J Cancer. 2012; 132(12):2948-55. DOI: 10.1002/ijc.27970. View

18.

Zimpfer A, Maruschke M, Rehn S, Kundt G, Litzenberger A, Dammert F . Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays. BJU Int. 2013; 114(2):296-302. DOI: 10.1111/bju.12487. View

19.

Erlmeier F, Feuchtinger A, Borgmann D, Rudelius M, Autenrieth M, Walch A . Supremacy of modern morphometry in typing renal oncocytoma and malignant look-alikes. Histochem Cell Biol. 2015; 144(2):147-56. DOI: 10.1007/s00418-015-1324-4. View

20.

Krebs M, Metcalf R, Carter L, Brady G, Blackhall F, Dive C . Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol. 2014; 11(3):129-44. DOI: 10.1038/nrclinonc.2013.253. View